Phase I/II Clinical Trial In CLL To Evaluate Combination Therapy With Biothera's Imprime PGG

[Guest guest]

BlankPhase I/II Clinical Trial In Chronic Lymphocytic Leukemia To Evaluate

Combination Therapy With Biothera's Imprime PGG

16 Mar 2011

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia (CLL)

recently began receiving a new combination treatment in a Phase I/II clinical

trial that researchers believe could result in a more effective therapy for this

disease, Biothera announced this week.

The study will evaluate Biothera's Imprime PGG® in combination with alemtuzumab

(Campath®) and rituximab (Rituxan®). Imprime PGG is a developmental drug that

binds to and directs neutrophils, the most abundant type of immune cell in the

body, to kill cancer. Imprime PGG works synergistically with anti-tumor

monoclonal antibodies, such as alemtuzumab and rituximab.

" Imprime PGG's unique mechanism of action, which engages and directs innate

immune cells to kill cancer, has been successfully demonstrated in multiple

clinical and preclinical studies involving several types of cancer, " said Dan

Conners, president of Biothera's Pharmaceutical Group. " We are confident that

combining Imprime PGG with Rituxan and Campath will result in similarly

significant improvements in outcomes for CLL patients. "

Full story

http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=219184